Structure Therapeutics (GPCR) Cash from Operations (2022 - 2026)

Structure Therapeutics' Cash from Operations history runs 5 years deep, the most recent figure standing at 15234000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 129.17% year-over-year to 15234000.0; the TTM figure through Mar 2026 stood at 154736000.0 (down 14.8% YoY), while the FY2025 annual figure was 222199000.0, down 90.51% from the prior year.
• Cash from Operations for Q1 2026 stood at 15234000.0, up from 64416000.0 in the prior quarter.
• The five-year high for Cash from Operations was 15234000.0 in Q1 2026, with the low at 64416000.0 in Q4 2025.
• The 5-year median for Cash from Operations is 20557000.0 (2023), against an average of 26424058.82.
• The sharpest annual moves came in 2025 and 2026: Cash from Operations tumbled 158.92% in 2025, then jumped 129.17% in 2026.
• Structure Therapeutics' Cash from Operations stood at 12026000.0 in 2022, then slumped by 80.68% to 21729000.0 in 2023, then slumped by 67.83% to 36467000.0 in 2024, then tumbled by 76.64% to 64416000.0 in 2025, then surged by 123.65% to 15234000.0 in 2026.
• Business Quant data shows GPCR's Cash from Operations at 15234000.0 in Q1 2026, 64416000.0 in Q4 2025, and 50996000.0 in Q3 2025.